AI 聊天
Loading data for FEED — first visit, this takes a few seconds.

ENvue Medical, Inc.

FEED · NasdaqCM · USD

3.35 -0.23 (-6.42%)

收盤價: Sep 14, 2026, 3:59 PM

3.47 +3.58%

盤後: 6:34 PM

市值
$3.09M
成交量
21.9K

ENvue Medical, Inc.(FEED)股價、分析與資料

內在價值

正在載入內在價值…

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識: n/a

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →

正在載入...

最新財報

已通報較預期YoY 變更
營收$239.0Kn/a-51.62%
EPS-$3168,00+$2112,00+65.71%

下次財報

查看財報詳情 →

指標

買價
2.53
市值
3.09M
淨利(ttm)
-49.2M
1.38
-302.64
n/a
n/a
P/B (ttm)
0.07
P/S (ttm)
1.61
財報日期
n/a
賣價
4.37
成交量
21,886
20 日平均成交量
71,356
開盤價
3.58
前收盤價
3.58
當日區間
3.33 - 3.58
52 週範圍
3.33 - 208.80
股利
n/a
除息日
n/a

關於 ENvue Medical, Inc.

查看公司資料 →
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas. Medical Devices · Healthcare

ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.

類股 Healthcare
IPO 日期 May 28, 2015
員工 12
證券交易所 NasdaqCM
股票代號 FEED